Acute respiratory infection is now the leading cause of mortality in young children under 5 years of age, accounting for nearly one fifth (20%) of childhood deaths worldwide. Human parainfluenza viruses (HPIVs) and respiratory syncytial virus (RSV) are paramyxoviruses that cause the majority of childhood croup, bronchiolitis and pneumonia in the U.S. Despite the impact of these diseases on illness and hospitalization of young infants worldwide, no drugs or vaccines are available. With this application, we are poised to develop a new broad-spectrum antiviral strategy based on inhibiting fusion during viral entry. We found that lipid-conjugated peptides derived from the fusion protein of HPIV3 block fusion intermediates during viral entry and inhibit both HPIV and RSV infection. By combining structure-based optimization of fusion inhibitors, backbone modification to enhance half-life, and modification of lipid components with virologic and in vivo assays, we aim to identify and characterize novel HPIV3/RSV fusion inhibitors that can be administered intranasally and have significantly improved antiviral efficacy. Bio distribution studies in animals show that a single intranasal administration of our lead HPIV3 peptide inhibitor generates adequate antiviral concentrations in the lung. We will exploit the uniquely broad antiviral activity of our prototype HPIV3 derived peptides to test our hypothesis that lipid linkage combined with peptide backbone modification can deliver potent antiviral agents. We plan to determine the optimal dose regimens and routes of delivery, and to develop a useful, easily deliverable, short-term acting antiviral product. By combining the two recent innovations -- membrane targeting and backbone modification -- we aim to generate effective anti-HPIV/RSV inhibitors for human disease, via the following two Specific Aims.
Aim 1. Identify and develop optimized membrane-targeted anti-HPIV3 and anti-RSV broad spectrum peptide inhibitors. We will combine conventional peptide design (a residue side chain modification) with backbone-modification (a replacement) and lipid-based membrane targeting to optimize fusion inhibition activity. These efforts will be guided by biophysical and cell-based measurements.
Aim 2. Effectiveness of broad spectrum membrane-targeted C-peptide inhibitors to protect against respiratory infection in animal models of human HPIV3 and RSV infection. Challenge experiments in cotton rats - an ideal small animal model for both HPIV3 and RSV infection - will determine the required dose for therapeutic efficacy, and the therapeutic time window. We propose that backbone modification and membrane targeting strategies may be synergistic, and that their combination will generate antiviral agents that can be delivered intranasally with unprecedented efficacy and pharmacokinetic properties. Iterative cycling among design efforts and in vitro and in vivo studies should lead to promising investigational anti-HPIV/RSV agents.

Public Health Relevance

Respiratory Syncytial Virus (RSV) and Human parainfluenza viruses are a major cause of childhood croup, bronchiolitis and pneumonia in the U.S., yet despite the huge impact of these diseases on illness and hospitalization of young children worldwide, no drugs or vaccines are available. We propose to apply the results of our fundamental research to develop a new antiviral strategy that is based on inhibiting fusion during viral entry. Effective therapy for pediatric respiratory viruses would significantly decreas morbidity and mortality due to lower respiratory disease for children, the elderly and the immunocompromised in the U.S. and worldwide.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI114736-05
Application #
9640216
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Kim, Sonnie
Project Start
2015-02-01
Project End
2020-01-31
Budget Start
2019-02-01
Budget End
2020-01-31
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Pediatrics
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Iketani, Sho; Shean, Ryan C; Ferren, Marion et al. (2018) Viral Entry Properties Required for Fitness in Humans Are Lost through Rapid Genomic Change during Viral Isolation. MBio 9:
Figueira, Tiago N; Mendonça, Diogo A; Gaspar, Diana et al. (2018) Structure-Stability-Function Mechanistic Links in the Anti-Measles Virus Action of Tocopherol-Derivatized Peptide Nanoparticles. ACS Nano 12:9855-9865
Mathieu, Cyrille; Porotto, Matteo; Figueira, Tiago N et al. (2018) Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates. J Infect Dis 218:218-227
Mathieu, Cyrille; Augusto, Marcelo T; Niewiesk, Stefan et al. (2017) Broad spectrum antiviral activity for paramyxoviruses is modulated by biophysical properties of fusion inhibitory peptides. Sci Rep 7:43610
Figueira, T N; Palermo, L M; Veiga, A S et al. (2017) In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence. J Virol 91:
Chen, Ya-Wen; Huang, Sarah Xuelian; de Carvalho, Ana Luisa Rodrigues Toste et al. (2017) A three-dimensional model of human lung development and disease from pluripotent stem cells. Nat Cell Biol 19:542-549
Figueira, Tiago N; Freire, João M; Cunha-Santos, Catarina et al. (2017) Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance. Sci Rep 7:45647
Augusto, Marcelo T; Hollmann, Axel; Porotto, Matteo et al. (2017) Antiviral Lipopeptide-Cell Membrane Interaction Is Influenced by PEG Linker Length. Molecules 22:
Palermo, Laura M; Uppal, Manik; Skrabanek, Lucy et al. (2016) Features of Circulating Parainfluenza Virus Required for Growth in Human Airway. MBio 7:e00235